Novartis Reports 19.1% Lower Death Risk in Six-Year Kisqali Analysis

Novartis' remibrutinib, an oral BTK inhibitor, reduced annualized relapse rate by 35.2% and 31.2% in two phase 3 trials for relapsing multiple sclerosis (RMS) compared to teriflunomide. The trials also showed improvements in disability progression and MRI outcomes. Novartis plans to seek global regulatory approval for remibrutinib in RMS.

Novartis reported relapse data for its multiple sclerosis drug remibrutinib that fell short of expectations. The company's shares have seen a 5-day change of 128.00 CHF, a 1st Jan change of -0.68%, and a year-to-date increase of 16.79%.

Novartis presented Phase III study results for remibrutinib, showing a 35.2% and 31.2% reduction in annual relapse rates for relapsing multiple sclerosis compared to Sanofi's Aubagio. The drug showed a favorable safety profile, potentially aiding market competition, according to STAT News.

Novartis's U.S. shares dropped 4.5% after presenting MS pill trial data showing relapse rate reductions of 35.2% and 31.2% vs. Sanofi's Aubagio, below Roche's 51.1%-58.5% with fenebrutinib. No liver safety issues were observed. Analysts expected at least parity in efficacy. Novartis aims for long-term disease management.

Novartis' MS drug remibrutinib reduced relapse rates by 35.2% and 31.2% in Phase 3 trials compared to Sanofi's Aubagio, according to data presented at a conference. The drug showed a cleaner safety profile but less efficacy than Roche's rival treatment.

Novartis reported that its experimental MS pill, remibrutinib, showed significant reductions in symptom flare-ups (35.2% and 31.2%) compared to Sanofi's Aubagio in late-stage trials. The drug demonstrated a favorable safety profile with no observed liver safety signals, according to the company.